FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting

HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics, will present on FibroBiologics’ unique fibroblast cell-based approach for the potential treatment of chronic diseases at The German-Nordic Joint Extracellular Matrix Meeting in Freiburg, Germany, from March 26-28, 2025. The joint meeting is an annual opportunity to showcase advances in extracellular matrix biology.

Read more at globenewswire.com